近日，2025首届健康科技与科普大会(下称：科普大会)在海南圆满落幕，此次会议以"AI引领健康科普 新时代"为主题，汇聚了健康科技领域的专家学者、行业从业者及科普工作者，共同探讨了AI技术在健 康科普与慢病管理中的深度融合与应用前景。 会上，方舟云康旗下慢病管理健康科普平台"方舟医聊"(以下称：方舟医聊)凭借创新实践与卓越传播成 效，斩获年度优秀科普传播作品"最佳创新作品"大奖，其科普内容曝光量已突破12亿次，成为健康科普 领域的标杆范本。 深耕慢病管理领域，打造精准科普体系 方舟云康作为深耕慢病管理领域多年的企业，始终致力于通过技术手段提升患者的自我管理能力与生活 质量。企业明确，改变患者从"被动认知"到"主动管理"的行为模式，是提升慢病管理效果的关键。基于 这一洞察，方舟云康于2021年推出了慢病管理健康科普平台"方舟医聊"。 该平台依托方舟云康在H2H(Hospital to Home从医院到家庭)智慧医疗业务生态体系中积累的丰富服务经 验与雄厚技术能力，旨在通过精准、体系化的科普内容，帮助慢病患者建立科学认知、养成健康习惯， 进一步完善慢病管理全生命周期服务。 值得关注的是，方舟医聊平台构建的"文章+ ...

中证报中证网讯(王珞)方舟云康控股有限公司(股票简称方舟健客，股票代码06086.HK)12月8日公告宣 布，谢方敏辞任本公司董事会主席、提名委员会主席及成员、首席执行官及授权代表的职位，自2025年 12月7日起生效。 董事会表示，尊重其决定，并对其在任期间对公司发展所作出的贡献表示感谢。谢方敏由执行董事重新 委任为非执行董事，将继续以其丰富的经验为公司发展提供指导。 董事会同时表示，已决议委任现任非执行董事David McKee HAND为主席，并自2025年12月7日起生 效。董事会已要求提名委员会开始正式搜寻新首席执行官人选，同时考虑内部及外部候选人，以找到最 合适的继任者带领公司向前发展。 根据公告，上述系列安排均在公司健全的治理机制下有序推进，现有战略和日常业务经营不受影响。董 事会及新任领导团队将继续致力于推动公司稳健发展。 作为创始人和领导者，自2015年公司成立以来，谢方敏始终聚焦公司的长期发展、深耕战略布局。在医 药行业转型升级的关键节点，谢方敏带领团队突破瓶颈，推动公司完成从医药电商到"AI+慢病管理"头 部企业的升级，并于2024年成功在香港联交所主板上市。转任非执行董事后，他将继续凭 ...

Core Viewpoint - The collaboration between Fangzhou Yunkang and Tencent Health aims to integrate technology and practical scenarios to provide comprehensive support for the "AI + Chronic Disease Management" solution, promoting the intelligent, compliant, and efficient transformation of the internet healthcare industry [1][2]. Group 1: Policy Empowerment - The recent policies from the 20th Central Committee of the Communist Party of China emphasize the implementation of "Artificial Intelligence +" actions, accelerating the integration of AI in the healthcare sector [2]. - The joint initiative by Fangzhou Yunkang and Tencent Health responds to these policies, aiming to enhance the accessibility and quality of healthcare services through AI [2]. Group 2: Technological Integration - Fangzhou Yunkang's "AI + H2H (Hospital to Home) Smart Medical Ecosystem" combines its expertise in chronic disease management with Tencent Health's advanced technological capabilities, creating a robust solution for the industry [3]. - The "AI + Chronic Disease Management" solution leverages Tencent Health's TI platform for efficient model optimization, aligning closely with real business needs [3]. Group 3: Performance and Impact - The effectiveness of the solution is evidenced by a significant 2.4 times increase in the user base for AI functionalities on the platform in October, indicating strong growth [4]. - Features like the "Report Interpretation" function on the Jianke Doctor APP address common patient challenges, enhancing user engagement and platform dependency [4]. - The AI Health Steward provides 24/7 health consultations and intelligent triage, while the AI Medication Assistant offers a photo recognition feature, improving service efficiency and user experience [4]. Group 4: Future Outlook - The company plans to deepen strategic collaborations with Tencent Health and other industry partners to continuously optimize the "AI + Chronic Disease Management" solution, aiming to provide smarter and more reliable services [5].

Core Viewpoint - The collaboration between Ark Health and Tencent Health marks a new development phase in the domestic chronic disease management sector, providing comprehensive support for technological validation, scenario implementation, and large-scale deployment in the industry [1][5]. Group 1: AI and Chronic Disease Management - The "AI + Chronic Disease Management" solution is based on Ark Health's effective practices in the field, demonstrating significant value through substantial business data, with a 2.4 times increase in AI function experience user volume in October [1][2]. - The AI technology effectively addresses user pain points, such as the common difficulty patients face in understanding medical reports, leading to increased user engagement and trust in the AI functionalities [2][3]. Group 2: Technical Foundation and Security Measures - The solution is built on a solid technical foundation, utilizing Tencent Health's TI platform to create a large model base, enabling efficient fine-tuning and continuous optimization of models [3][4]. - Ark Health has implemented multiple security measures to ensure reliable application in the sensitive medical field, including knowledge base optimization and compliance upgrades to mitigate risks associated with large models [2][3]. Group 3: Industry Collaboration and Policy Response - The partnership aims to integrate Ark Health's AI capabilities with Tencent Health's comprehensive service capabilities, facilitating safe, efficient, and compliant digital upgrades for industry partners [3][5]. - This collaboration aligns with recent policy initiatives from the National Health Commission and other departments to promote and regulate the application of AI in healthcare, positioning AI medical solutions as a vital component of public health infrastructure [5]. Group 4: Future Outlook - Ark Health plans to continue driving technological innovation and deepen collaborations with Tencent Health and other industry partners, aiming to enhance chronic disease management services towards greater efficiency, precision, and accessibility [5].

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - The strategic partnership between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. aims to explore innovative approaches in the health industry empowered by AI [1][6] Industry Trends - The National Health Commission issued guidelines promoting the application of AI in healthcare, outlining core goals and pathways for the next five years [2] - The aging population and the increasing prevalence of chronic diseases in younger demographics highlight the critical role of AI technology in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Dr. Xie Fangmin, emphasized the importance of addressing real problems and driving genuine change in chronic disease management through AI [2][4] - The user engagement with the "AI Health Steward" platform has significantly increased, with user numbers in October being 2.4 times that of September and GMV rising by 50% [4] Strategic Collaborations - The partnership with Wangshan Wangshui is designed to integrate technological empowerment with product pipeline advantages, aiming for a comprehensive upgrade from drug supply to health services [6][8] - Both companies plan to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of development in the health industry [5][6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - A strategic partnership was formed between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., aimed at integrating core industry resources with digital technology capabilities [1][5] Industry Trends - The Chinese government has emphasized the importance of "AI+" in various sectors, particularly in healthcare, as outlined in the recent policy documents [2] - The aging population and the increasing prevalence of chronic diseases in China present significant opportunities for AI applications in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Xie Fangmin, highlighted the company's commitment to solving real problems in chronic disease management through AI technology [2][4] - The company reported a 2.4 times increase in users experiencing AI features in October compared to September, with a 50% increase in Gross Merchandise Volume (GMV) [4] Strategic Collaboration - The partnership between Fangzhou Jianke and Wangshan Wangshui aims to break down industry barriers and enhance the entire health service chain from drug supply to health services [5][6] - Both companies plan to leverage their respective strengths to create a customer-centric health service system, providing comprehensive health management solutions [5][6] Future Outlook - The collaboration is expected to facilitate a more efficient connection between biopharmaceutical research and health services, ensuring that research outcomes meet user needs [6] - Fangzhou Jianke aims to continue its focus on chronic disease management and enhance its technological foundation to drive digital upgrades in health services [6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] Group 1: Strategic Partnerships - Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. announced a strategic cooperation aimed at integrating core industry resources with digital technology capabilities [1][5] - The partnership is designed to break down industry barriers and achieve a full-chain upgrade from drug supply to health services [5][6] Group 2: AI and Chronic Disease Management - The Chinese government has emphasized the importance of "AI + healthcare," providing a clear direction for the industry's development over the next five years [2][4] - Ark Health's CEO highlighted the critical role of AI in addressing the challenges posed by an aging population and the increasing prevalence of chronic diseases [2][4] Group 3: Technological Advancements - The application of AI technology has led to significant user engagement, with a 2.4 times increase in users experiencing AI features in October compared to September, and a 50% increase in GMV [4] - The company aims to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of health services [4][6] Group 4: Future Outlook - The collaboration is expected to enhance the alignment between biopharmaceutical research and health service delivery, ensuring that research outcomes meet user needs more effectively [6] - Ark Health plans to continue deepening its focus on chronic disease management and strengthening its technological foundation to drive the digital transformation of health services [6]

Core Insights - The article discusses the successful convening of the Ark Health (方舟健客) Double 12 Core Partner Summit, focusing on the theme "Collaborative Win-Win, Intelligent Future," which gathered key players in the internet healthcare industry to explore the enhancement of chronic disease management through artificial intelligence [1][2] - A strategic partnership was announced between Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. (旺山旺水), aimed at integrating core industry resources with digital technology capabilities to drive innovation in the health industry [1][6] Industry Trends - The Chinese government has emphasized the importance of "AI+" initiatives across various sectors, including healthcare, as part of its strategic direction for the next five years [1][2] - The aging population and the increasing prevalence of chronic diseases among younger individuals highlight the critical role AI technology can play in healthcare [2] Company Developments - Ark Health's CEO, Dr. Xie Fangmin, highlighted the company's commitment to addressing real problems and delivering tangible changes in chronic disease management through AI applications [2][5] - The company reported a significant increase in user engagement with its AI features, with a 2.4 times increase in users experiencing AI functionalities and a 50% rise in Gross Merchandise Volume (GMV) in October compared to September [4] Strategic Collaboration - The partnership between Ark Health and Wangshan Wangshui is designed to break down industry barriers and integrate technological empowerment with product pipeline advantages, facilitating a comprehensive upgrade from drug supply to health services [5][6] - Both companies aim to create a customer-centric health service system, providing tailored, efficient, and professional health management solutions throughout the entire lifecycle [6][8] Future Outlook - The collaboration is expected to enhance the connection between biopharmaceutical research and health services, ensuring that research outcomes align more closely with user needs [8] - Ark Health plans to continue its focus on chronic disease management, strengthening its technological foundation and enhancing application scenarios to promote digital transformation in health services [9]

Core Insights - Ark Health has been recognized for its pioneering efforts in the "AI + chronic disease management" sector, receiving the "Social Responsibility Golden Bull Award" at the 2025 Xiamen Industrial Development Conference [1] - The company has developed the "Xingjie Large Model," an AI super brain that enhances health services for chronic disease patients by shifting from passive responses to proactive predictions [1][2] - Under the leadership of CEO Xie Fangmin, Ark Health has introduced innovative solutions like the "AI Weight Loss Consultant," which has garnered positive feedback during its showcase at the China International Import Expo [1][2] Company Developments - Ark Health has created the first "AI + weight loss" digital solution in the industry, responding to the increasing prevalence of obesity as a major factor in chronic diseases [2][3] - The company is actively participating in the "Healthy China AI + Weight Management Pioneer" initiative, collaborating with the China Food and Drug Administration to establish industry standards and promote scientific weight loss concepts [3] - A strategic partnership was formed with Novo Nordisk to explore innovative management models for diabetes and obesity, indicating a commitment to comprehensive chronic disease management [3] Industry Context - The rise in obesity rates is linked to an increase in chronic diseases such as cardiovascular diseases and diabetes, highlighting the need for effective weight management solutions [2] - The Chinese government has issued guidelines encouraging the development of "AI + health industry" services, creating a favorable environment for companies like Ark Health to innovate and integrate AI technology into chronic disease management [2][3] - The focus on AI applications in healthcare is expected to drive digital transformation in health management, redefining the boundaries and possibilities of chronic disease management [3]

Core Viewpoint - The article highlights the recognition of Fangzhou Jianke for its innovative contributions in the "AI + chronic disease management" sector, emphasizing its role as a benchmark in the healthcare industry and its commitment to social responsibility [1][4]. Group 1: Awards and Recognition - Fangzhou Jianke received the "Social Responsibility Golden Bull Award" at the 2025 Xiamen Industrial Development Conference, acknowledging its forward-looking exploration and breakthrough technological achievements in the healthcare sector [1]. - The Golden Bull Award is a prestigious evaluation activity by China Securities Journal, emphasizing transparency and professionalism in recognizing high-quality development among Hong Kong-listed companies [3]. Group 2: Technological Innovation and Strategy - The company has integrated AI technology into its operations, creating a new ecosystem called AI + H2H (Hospital To Home), which enhances the efficiency and accuracy of chronic disease management [4]. - Fangzhou Jianke's AI technology has been recognized as a key driver for high-quality development in the healthcare sector, aligning with national policies promoting AI in medical applications [4]. Group 3: Social Impact and Community Engagement - The company has established partnerships, such as the AI + Viral Hepatitis Prevention and Control Training Base with the Guangdong Provincial Liver Disease Research Institute, to empower healthcare for liver disease patients [5]. - Fangzhou Jianke actively participates in rural revitalization initiatives, leveraging AI to improve healthcare accessibility in remote areas, thereby reducing time and medical costs for underserved populations [5]. Group 4: Future Directions - The company aims to continue leading in the digital transformation of chronic disease management while promoting high-quality development in the healthcare industry through technological empowerment [6].